Pacira BioSciences, Inc.

PCRX Healthcare Drug Manufacturers Specialty & Generic

Pacira BioSciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $726.4 million, up 3.63% from fiscal 2024. In the quarter to June 2026, revenue grew 6.24%, EPS grew 209.1%, free cash flow grew 502.5% and total debt fell 37.4%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

36.35 0.02 +0.06%
Market cap
$1.5B
P/E
104×
Fwd P/E
33.7×
Dividend yield
—
F-score
8/9
Altman Z
2.02
Beneish M
−2.93
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
72.49 188.33 172.53 56.02

+8 more quarters

P/S ratio
1.34 1.24 1.59 1.58
P/FCF ratio
5.58 6.89 8.44 9.14
P/Operating CF
17.42 35.61 26.40 18.66
P/B ratio
1.49 1.40 1.66 1.56
EV/Sales
1.76 1.74 2.05 2.05
EV/EBITDA
12.77 11.21 13.76 11.44
EV/FCF
7.33 9.66 10.90 11.82
Current Ratio
5.04 4.73 4.54 5.26
Net Debt/EBITDA
4.10 5.86 6.92 4.65
Debt/Equity
0.54 0.56 0.54 0.52
Earnings Yield
1.38% 0.53% 0.58% 1.79%
Free Cash Flow Yield
17.93% 14.51% 11.85% 10.94%
Free Cash Flow per Share
1.42 0.57 0.98 1.29
Book value per Share
17.03 16.16 15.55 16.51
Free Cash Flow
56.12 22.96 43.47 56.96
EV/EBIT
66.21 53.20 77.62 35.32
Other line items

Show all line items

Columns are period end dates